1. Approval of Unaudited Standalone Financial Results for Q1 FY27

The Board approved the unaudited standalone financial results for the quarter ended June 30, 2026. The results were reviewed by Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration No: 001076N/N500013), who issued an unmodified limited review report pursuant to Regulation 33 of the Listing Regulations. The financials are prepared in accordance with Ind AS 34.

Key Financial Figures (₹ in Lakhs):

  • Total Income: ₹16,644.31
  • Total Expenses: ₹14,998.48
  • Profit Before Exceptional Items and Tax: ₹1,645.83
  • Exceptional Items: ₹0.00 (Nil)
  • Profit Before Tax: ₹1,645.83
  • Total Tax Expense: ₹256.55
  • Profit After Tax from Continuing Operations: ₹1,389.28
  • Loss After Tax from Discontinued Operations: ₹(19.48)
  • Profit for the Period (Net Profit): ₹1,369.80
  • Other Comprehensive Income: ₹22.45
  • Total Comprehensive Income: ₹1,392.25
  • Paid-up Equity Share Capital (Face Value ₹5 per share): ₹1,683.13

Earnings Per Share (EPS) (in ₹):

  • Basic EPS (Continuing Operations): 4.13
  • Diluted EPS (Continuing Operations): 4.12
  • Basic EPS (Discontinued Operations): (0.06)
  • Diluted EPS (Discontinued Operations): (0.06)
  • Basic EPS (Total): 4.07
  • Diluted EPS (Total): 4.06

Comparative Figures (₹ in Lakhs):

  • Quarter Ended March 31, 2026 (Q4 FY26): Net Loss of ₹(2,285.06), impacted by an exceptional item of ₹(3,324.66) from reversal of technical know-how income.
  • Quarter Ended June 30, 2025 (Q1 FY26): Net Profit of ₹1,183.37

2. Continuation of Directorship of Mr. Gopalakrishnan Kesavan

The Board approved the continuation of Mr. Gopalakrishnan Kesavan (DIN: 02105656) as a Non-Executive Independent Director upon his attainment of the age of 75 years on January 3, 2027. This is in compliance with Regulation 17(1A) of the Listing Regulations and is subject to approval by the shareholders. His current term is set to expire on August 17, 2030.

Director Profile: Mr. Kesavan holds a B.Sc. in Biology and Chemistry from Kerala University and a Diploma in Management Studies from Mumbai University. He has extensive experience in pharmaceutical sales, marketing, and brand management, having held leadership positions with reputed pharmaceutical companies. He is not related to any other director of the company.

Notes to the Financial Results

Note 4: Discontinued Operations

The results include operations from units approved for sale/disposal. The financials from discontinued operations for the quarter are:

  • Total Income: ₹10.61 Lakhs
  • Total Expenses: ₹26.03 Lakhs
  • Loss Before Tax: ₹(26.03) Lakhs
  • Tax Credit: ₹(6.55) Lakhs
  • Loss After Tax: ₹(19.48) Lakhs

Note 6: Preferential Issue and Fund Utilization

On September 19, 2024, the company allotted 39,84,852 equity shares and 20,79,409 convertible warrants, raising ₹15,225.90 Lakhs. The balance 75% of the warrant issue price (₹5,271.30 Lakhs) was received in Q4 FY26. The warrants were converted into 20,79,409 equity shares on March 18, 2026, increasing the paid-up capital from ₹1,579.16 Lakhs (3,15,83,252 shares) to ₹1,683.13 Lakhs (3,36,62,661 shares). Listing approvals for these new shares were received from NSE and BSE in Q1 FY27.

Fund Utilization as of June 30, 2026:

  • Repayment of loan: Allocated ₹15,000.00 Lakhs; Utilized ₹15,000.00 Lakhs
  • Investment in capital expenditure: Allocated ₹3,500.00 Lakhs; Utilized ₹2,330.84 Lakhs; Unutilized ₹1,169.16 Lakhs
  • General corporate purposes: Allocated ₹1,997.00 Lakhs; Utilized ₹1,993.48 Lakhs; Unutilized ₹3.52 Lakhs
  • Total: Allocated ₹20,497.00 Lakhs; Utilized ₹19,324.32 Lakhs; Unutilized ₹1,172.68 Lakhs

Note 7: Exceptional Item in Q4 FY26

An income of ₹3,324.66 Lakhs, recognized in a prior year from a Transfer of Technical Know-how arrangement, was reversed in Q4 FY26 (March 31, 2026) due to the customer's inability to meet timelines caused by regional instability in the Middle East.

Note 8: Acquisition of Genrx Pharmaceuticals Private Limited

The company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) in April 2025 for a total consideration of ₹1,085.00 Lakhs. An application filed with the NCLT, Mumbai on June 3, 2025, for certain reliefs and concessions is still pending as of June 30, 2026. Consequently, Genrx has not been consolidated as control is not yet established under Ind AS 110.